View in EDS

The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.

Saved in:
Bibliographic Details
Title: The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Authors: Sudhakar N; Mirati Therapeutics, Inc., San Diego, California., Yan L; Mirati Therapeutics, Inc., San Diego, California., Qiryaqos F; Mirati Therapeutics, Inc., San Diego, California., Engstrom LD; Mirati Therapeutics, Inc., San Diego, California., Laguer J; Mirati Therapeutics, Inc., San Diego, California., Calinisan A; Mirati Therapeutics, Inc., San Diego, California., Hebbert A; Mirati Therapeutics, Inc., San Diego, California., Waters L; Mirati Therapeutics, Inc., San Diego, California., Moya K; Mirati Therapeutics, Inc., San Diego, California., Bowcut V; Mirati Therapeutics, Inc., San Diego, California., Vegar L; Mirati Therapeutics, Inc., San Diego, California., Ketcham JM; Mirati Therapeutics, Inc., San Diego, California., Ivetac A; Mirati Therapeutics, Inc., San Diego, California., Smith CR; Mirati Therapeutics, Inc., San Diego, California., Lawson JD; Mirati Therapeutics, Inc., San Diego, California., Rahbaek L; Mirati Therapeutics, Inc., San Diego, California., Clarine J; Mirati Therapeutics, Inc., San Diego, California., Nguyen N; Mirati Therapeutics, Inc., San Diego, California., Saechao B; Mirati Therapeutics, Inc., San Diego, California., Parker C; Mirati Therapeutics, Inc., San Diego, California., Elliott AJ; Mirati Therapeutics, Inc., San Diego, California., Vanderpool D; Mirati Therapeutics, Inc., San Diego, California., He L; Monoceros Biosciences LLC, San Diego, California., Hover LD; Monoceros Biosciences LLC, San Diego, California., Fernandez-Banet J; Monoceros Biosciences LLC, San Diego, California., Coma S; Verastem Oncology, Needham, Massachusetts., Pachter JA; Verastem Oncology, Needham, Massachusetts., Hallin J; Mirati Therapeutics, Inc., San Diego, California., Marx MA; Mirati Therapeutics, Inc., San Diego, California., Briere DM; Mirati Therapeutics, Inc., San Diego, California., Christensen JG; Mirati Therapeutics, Inc., San Diego, California., Olson P; Mirati Therapeutics, Inc., San Diego, California., Haling J; Mirati Therapeutics, Inc., San Diego, California., Khare S; Mirati Therapeutics, Inc., San Diego, California.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Oct 01; Vol. 23 (10), pp. 1418-1430.
Publication Type: Journal Article
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38904222
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sudhakar+N%22">Sudhakar N</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Yan+L%22">Yan L</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Qiryaqos+F%22">Qiryaqos F</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Engstrom+LD%22">Engstrom LD</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Laguer+J%22">Laguer J</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Calinisan+A%22">Calinisan A</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Hebbert+A%22">Hebbert A</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Waters+L%22">Waters L</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Moya+K%22">Moya K</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Bowcut+V%22">Bowcut V</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Vegar+L%22">Vegar L</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Ketcham+JM%22">Ketcham JM</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Ivetac+A%22">Ivetac A</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Smith+CR%22">Smith CR</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Lawson+JD%22">Lawson JD</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Rahbaek+L%22">Rahbaek L</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Clarine+J%22">Clarine J</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Nguyen+N%22">Nguyen N</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Saechao+B%22">Saechao B</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Parker+C%22">Parker C</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Elliott+AJ%22">Elliott AJ</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Vanderpool+D%22">Vanderpool D</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22He+L%22">He L</searchLink>; Monoceros Biosciences LLC, San Diego, California.<br /><searchLink fieldCode="AU" term="%22Hover+LD%22">Hover LD</searchLink>; Monoceros Biosciences LLC, San Diego, California.<br /><searchLink fieldCode="AU" term="%22Fernandez-Banet+J%22">Fernandez-Banet J</searchLink>; Monoceros Biosciences LLC, San Diego, California.<br /><searchLink fieldCode="AU" term="%22Coma+S%22">Coma S</searchLink>; Verastem Oncology, Needham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Pachter+JA%22">Pachter JA</searchLink>; Verastem Oncology, Needham, Massachusetts.<br /><searchLink fieldCode="AU" term="%22Hallin+J%22">Hallin J</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Marx+MA%22">Marx MA</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Briere+DM%22">Briere DM</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Christensen+JG%22">Christensen JG</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Olson+P%22">Olson P</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Haling+J%22">Haling J</searchLink>; Mirati Therapeutics, Inc., San Diego, California.<br /><searchLink fieldCode="AU" term="%22Khare+S%22">Khare S</searchLink>; Mirati Therapeutics, Inc., San Diego, California.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101132535%22">Molecular cancer therapeutics</searchLink> [Mol Cancer Ther] 2024 Oct 01; Vol. 23 (10), pp. 1418-1430.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%2C+Inc%22">American Association for Cancer Research, Inc </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101132535 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1538-8514 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215357163%22">15357163 </searchLink><i>NLM ISO Abbreviation: </i>Mol Cancer Ther <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38904222
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1535-7163.MCT-23-0870
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1418
    Titles:
      – TitleFull: The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sudhakar N
      – PersonEntity:
          Name:
            NameFull: Yan L
      – PersonEntity:
          Name:
            NameFull: Qiryaqos F
      – PersonEntity:
          Name:
            NameFull: Engstrom LD
      – PersonEntity:
          Name:
            NameFull: Laguer J
      – PersonEntity:
          Name:
            NameFull: Calinisan A
      – PersonEntity:
          Name:
            NameFull: Hebbert A
      – PersonEntity:
          Name:
            NameFull: Waters L
      – PersonEntity:
          Name:
            NameFull: Moya K
      – PersonEntity:
          Name:
            NameFull: Bowcut V
      – PersonEntity:
          Name:
            NameFull: Vegar L
      – PersonEntity:
          Name:
            NameFull: Ketcham JM
      – PersonEntity:
          Name:
            NameFull: Ivetac A
      – PersonEntity:
          Name:
            NameFull: Smith CR
      – PersonEntity:
          Name:
            NameFull: Lawson JD
      – PersonEntity:
          Name:
            NameFull: Rahbaek L
      – PersonEntity:
          Name:
            NameFull: Clarine J
      – PersonEntity:
          Name:
            NameFull: Nguyen N
      – PersonEntity:
          Name:
            NameFull: Saechao B
      – PersonEntity:
          Name:
            NameFull: Parker C
      – PersonEntity:
          Name:
            NameFull: Elliott AJ
      – PersonEntity:
          Name:
            NameFull: Vanderpool D
      – PersonEntity:
          Name:
            NameFull: He L
      – PersonEntity:
          Name:
            NameFull: Hover LD
      – PersonEntity:
          Name:
            NameFull: Fernandez-Banet J
      – PersonEntity:
          Name:
            NameFull: Coma S
      – PersonEntity:
          Name:
            NameFull: Pachter JA
      – PersonEntity:
          Name:
            NameFull: Hallin J
      – PersonEntity:
          Name:
            NameFull: Marx MA
      – PersonEntity:
          Name:
            NameFull: Briere DM
      – PersonEntity:
          Name:
            NameFull: Christensen JG
      – PersonEntity:
          Name:
            NameFull: Olson P
      – PersonEntity:
          Name:
            NameFull: Haling J
      – PersonEntity:
          Name:
            NameFull: Khare S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2024 Oct 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1538-8514
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: Molecular cancer therapeutics
              Type: main
ResultId 1